Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for hard-to-treat prostate cancer? drug targets genetic flaw

NCT ID NCT06029998

Recruiting now Disease control Sponsor: University of Utah Source: ClinicalTrials.gov ↗

First seen Jan 05, 2026 · Last updated Jun 11, 2026 · Updated 33 times

Summary

This study tests the drug bortezomib in 22 men with a specific genetic change (PTEN deletion) in their advanced prostate cancer that has stopped responding to hormone therapy. The main goal is to see if the drug can lower PSA levels by at least 30%. Participants receive bortezomib injections for up to 8 cycles (about 6 months).

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Huntsman Cancer Institute/University of Utah

    RECRUITING

    Salt Lake City, Utah, 84112, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Conditions inferred from the trial description

These were inferred from the trial's summary, not listed by the trial registrant.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WITH PTEN DELETION